Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 2/20 | 0.40 |
| ▸ | CDC25C | P30307 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 4/20 | 0.38 |
| ▸ | GRM5 | P41594 | 4/20 | 0.36 |
| ▸ | NQO1 | P15559 | 1/20 | 0.35 |
| ▸ | FABP6 | P51161 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
| ▸ | EED | O75530 | 1/20 | 0.32 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.32 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 2/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5108590 | 0.84 | MAOA (0.48) | CDC25ACDC25CMAOBNQO1MAOA | |
| SCHEMBL5117623 | 0.77 | MAOB (0.37) | CDC25ACDC25CMAOBGRM5DRD2 | |
| SCHEMBL5107324 | 0.76 | MAOA (0.54) | CDC25ACDC25CMAOBNQO1MAOA | |
| SCHEMBL5113287 | 0.73 | ESR1 (0.45) | CDC25ACDC25CNQO1MIFMAOA | |
| SCHEMBL1090921 | 0.70 | GRM5 (0.66) | MAOBGRM5PIK3CAPIK3CBMAOA | |
| SCHEMBL5122044 | 0.69 | MAOA (0.51) | MAOBMIFMAOAKDM4EALDH1A1 | |
| SCHEMBL5115307 | 0.69 | HPGD (0.51) | MAOBMAOAKDM4EALDH1A1GLA | |
| SCHEMBL12137350 | 0.68 | NQO1 (0.41) | CDC25ACDC25CNQO1ESR1 | |
| SCHEMBL5114993 | 0.68 | CA12 (0.43) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL5120765 | 0.66 | MEN1 (0.43) | CDC25ACDC25CMAOBNQO1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067619-B2 | Coumarin derivatives as ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-11-29 | — | — | US | disclosed |
| US-8067619-B2 | Coumarin derivatives as ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-11-29 | — | — | US | disclosed |
| US-20100069474-A1 | NOVEL COUMARIN DERIVATIVES AS ION CHANNEL OPENERS | JAIN NARESHKUMAR F | 2010-03-18 | — | — | US | disclosed |
| US-20100069474-A1 | NOVEL COUMARIN DERIVATIVES AS ION CHANNEL OPENERS | JAIN NARESHKUMAR F | 2010-03-18 | — | — | US | disclosed |
| US-7662975-B2 | trifluoro-methanesulfonic acid 3-(2,4-dimethoxy-phenyl)-4-(2-methoxy-ethyl)-2-oxo-2H-chromen-7-yl ester as potassium channel modulators; urinary incontinence, overactive bladder, hypertension, erectile dysfunction, female sexual disorders, dysmenorrhea, irritable bowl syndrome, airway hyperactivity | JANSSEN PHARMACEUTICA, NV (BE) | 2010-02-16 | — | — | US | disclosed |
| US-7662975-B2 | trifluoro-methanesulfonic acid 3-(2,4-dimethoxy-phenyl)-4-(2-methoxy-ethyl)-2-oxo-2H-chromen-7-yl ester as potassium channel modulators; urinary incontinence, overactive bladder, hypertension, erectile dysfunction, female sexual disorders, dysmenorrhea, irritable bowl syndrome, airway hyperactivity | JANSSEN PHARMACEUTICA, NV (BE) | 2010-02-16 | — | — | US | disclosed |
| US-7662975-B2 | trifluoro-methanesulfonic acid 3-(2,4-dimethoxy-phenyl)-4-(2-methoxy-ethyl)-2-oxo-2H-chromen-7-yl ester as potassium channel modulators; urinary incontinence, overactive bladder, hypertension, erectile dysfunction, female sexual disorders, dysmenorrhea, irritable bowl syndrome, airway hyperactivity | JANSSEN PHARMACEUTICA, NV (BE) | 2010-02-16 | — | — | US | disclosed |
| US-20070037877-A1 | trifluoro-methanesulfonic acid 3-(2,4-dimethoxy-phenyl)-4-(2-methoxy-ethyl)-2-oxo-2H-chromen-7-yl ester as potassium channel modulators; urinary incontinence, overactive bladder, hypertension, erectile dysfunction, female sexual disorders, dysmenorrhea, irritable bowl syndrome, airway hyperactivity | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037877-A1 | trifluoro-methanesulfonic acid 3-(2,4-dimethoxy-phenyl)-4-(2-methoxy-ethyl)-2-oxo-2H-chromen-7-yl ester as potassium channel modulators; urinary incontinence, overactive bladder, hypertension, erectile dysfunction, female sexual disorders, dysmenorrhea, irritable bowl syndrome, airway hyperactivity | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037877-A1 | trifluoro-methanesulfonic acid 3-(2,4-dimethoxy-phenyl)-4-(2-methoxy-ethyl)-2-oxo-2H-chromen-7-yl ester as potassium channel modulators; urinary incontinence, overactive bladder, hypertension, erectile dysfunction, female sexual disorders, dysmenorrhea, irritable bowl syndrome, airway hyperactivity | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069474-A1 | NOVEL COUMARIN DERIVATIVES AS ION CHANNEL OPENERS | KCNJ2, KCNN3, KCNN2 | CDC25A 4166/4885CDC25C 3521/4885MAOB 3884/4885 |
| US-20070037877-A1 | trifluoro-methanesulfonic acid 3-(2,4-dimethoxy-phenyl)-4-(2-methoxy-ethyl)-2-oxo-2H-chromen-7-yl ester as potassium channel modulators; urinary incontinence, overactive bladder, hypertension, erectile dysfunction, female sexual disorders, dysmenorrhea, irritable bowl syndrome, airway hyperactivity | KCNN2, KCNH3, KCNN1 | CDC25A 4243/4885CDC25C 4079/4885MAOB 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.